Co-Diagnostics (NASDAQ: CODX) reported Q3 EPS of $0.38, $0.17 better than the analyst estimate of $0.21. Revenue for the quarter came in at $30.1 million versus the consensus estimate of $24.32 million.

GUIDANCE:

Co-Diagnostics sees FY2021 EPS of $1.07-$1.16, versus the consensus of $0.98. Co-Diagnostics sees FY2021 revenue of $96-100 million, versus the consensus of $95.2 million.

For earnings history and earnings-related data on Co-Diagnostics (CODX) click here.